Apalutamide and Overall Survival in Prostate Cancer
Abstract
The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median metastasis-free survival (MFS) by 2 yr and overall survival (OS) data were immature.We report the prespecified event-driven final analysis for OS.A total of 1207 patients with nmCRPC (diagnosed by...
Paper Details
Title
Apalutamide and Overall Survival in Prostate Cancer
Published Date
Jan 1, 2021
Journal
Volume
79
Issue
1
Pages
150 - 158
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History